These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3299308)

  • 61. The role of serotonin in cardiovascular disease.
    Frohlich ED
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S1-2. PubMed ID: 2446053
    [No Abstract]   [Full Text] [Related]  

  • 62. Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin.
    Frishman WH; Okin S; Huberfeld S
    Med Clin North Am; 1988 Mar; 72(2):501-22. PubMed ID: 3279288
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Characteristics of the treatment of patients with hypertension associated with cervical osteochondrosis].
    Titieva NM
    Kardiologiia; 1987 Aug; 27(8):87-8. PubMed ID: 3682588
    [No Abstract]   [Full Text] [Related]  

  • 64. Ketanserin for hypertension after upper gastrointestinal surgery.
    Bogle RG
    Lancet; 1991 May; 337(8751):1219-20. PubMed ID: 1673753
    [No Abstract]   [Full Text] [Related]  

  • 65. [Symposium. Ketanserin: Serotonin antagonism is a new therapeutic principle in the older hypertensive patient. 24 September 1988, Frankfurt. Abstracts].
    Internist (Berl); 1988 Dec; 29(12 Suppl):1-12. PubMed ID: 3065279
    [No Abstract]   [Full Text] [Related]  

  • 66. [Cardiovascular pharmacology of serotonin and its antagonists].
    Van Nueten JM
    Rev Med Liege; 1988 Mar; 43 Suppl 1():22-30. PubMed ID: 3287545
    [No Abstract]   [Full Text] [Related]  

  • 67. Effect of the 5-HT2 antagonist ketanserin on the ECT-induced prolactin release.
    Zis AP; Manji HK; Remick RA; Grant BE; Clark CM
    Biol Psychiatry; 1989 May; 26(1):102-6. PubMed ID: 2655718
    [No Abstract]   [Full Text] [Related]  

  • 68. [Drug-induced hypertension in the treatment of arterial occlusive diseases].
    Mörl H; Diehm C; Mechtersheimer U
    Vasa; 1981; 10(2):151-5. PubMed ID: 6113719
    [No Abstract]   [Full Text] [Related]  

  • 69. Serotonin and cardiovascular regulation: a new approach to hypertension.
    Zanchetti A
    J Hypertens Suppl; 1986 Apr; 4(1):S37-8. PubMed ID: 2939212
    [No Abstract]   [Full Text] [Related]  

  • 70. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.
    Egermayer P; Town GI; Peacock AJ
    Thorax; 1999 Feb; 54(2):161-8. PubMed ID: 10325923
    [No Abstract]   [Full Text] [Related]  

  • 71. The role of serotonin in cardiovascular disease. Proceedings of a symposium. Kyoto, 27 May 1988.
    Drugs; 1988; 36 Suppl 1():1-151. PubMed ID: 3240720
    [No Abstract]   [Full Text] [Related]  

  • 72. Brain 5-HT1A receptor agonism: a novel mechanism for antihypertensive action.
    Saxena PR; Villalón CM
    Trends Pharmacol Sci; 1990 Mar; 11(3):95-6. PubMed ID: 2104465
    [No Abstract]   [Full Text] [Related]  

  • 73. [Observations with ketanserin].
    Reijnders PJ
    Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1187-8. PubMed ID: 2747814
    [No Abstract]   [Full Text] [Related]  

  • 74. Mechanism of antihypertensive action of ketanserin in man.
    Ball SG; Zabludowski JR; Robertson JI
    Br Med J (Clin Res Ed); 1983 Oct; 287(6398):1065. PubMed ID: 6412949
    [No Abstract]   [Full Text] [Related]  

  • 75. [The effect of pharmacologic blockade of serotonin receptors (S2) on arterial pressure in rats with 2 forms of hereditary arterial hypertension].
    Popova NK; Piianzin AI; Markel' AL
    Farmakol Toksikol; 1989; 52(6):58-61. PubMed ID: 2516487
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
    Podoleanu D; Cotoi S
    Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
    Lüscher TF; Tanner FC; Bühler FR
    Dtsch Med Wochenschr; 1992 Apr; 117(18):710-9. PubMed ID: 1572260
    [No Abstract]   [Full Text] [Related]  

  • 79. [Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
    Wiecek A; Grzeszczak W
    Pol Tyg Lek; 1987 Mar; 42(10):304-8. PubMed ID: 3299308
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.